<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141412">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02137083</url>
  </required_header>
  <id_info>
    <org_study_id>Fudan BR2014-13</org_study_id>
    <nct_id>NCT02137083</nct_id>
  </id_info>
  <brief_title>A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer</brief_title>
  <official_title>A Prospective Single-center Randomized Phase 3 Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Postmenopausal, Hormone-receptor Positive and HER2-negative Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparing Docetaxel Plus Fulvestrant With Docetaxel in Patients With Metastatic Breast
      Cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparing Docetaxel Plus Fulvestrant With Docetaxel in Postmenopausal, Hormone-receptor
      Positive and HER2-negative Metastatic Breast Cancer
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>6 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>6 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel Plus Fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel:75mg/m2 D2 every 21 days
Fulvestrant:500mg D1, D15, D29, D57, every 28 days later</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel:75mg/m2 D2 every 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>75mg/m2 D2 every 21 days</description>
    <arm_group_label>Docetaxel Plus Fulvestrant</arm_group_label>
    <arm_group_label>Docetaxel</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>500mg D1, D15, D29, D57, every 28 days later</description>
    <arm_group_label>Docetaxel Plus Fulvestrant</arm_group_label>
    <other_name>Faslodex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal female between 18 and 70 years old

          -  ECOG performance status of ≤ 1

          -  Life expectancy more than 3 months

          -  Histologically confirmed metastatic breast cancer

          -  ER and&amp;or PR pqositive, HER2-negative

          -  Disease progression during adjuvant or first-line endocrine therapy, or endocrine
             naive but unsuitable for endocrine therapy alone

          -  No pretreated chemotherapy for metastatic disease

          -  Have at least one target lesion according to RECIST 1.1

          -  No therapy (chemotherapy, endocrine therapy, target therapy and operation) within 4
             weeks before enrollment

          -  Hemoglobin ≥ 90 g/L, Absolute Neutrophil Count ≥ 1.5×10^9/L, Platelet Count ≥
             75×10^9/L, Serum Bilirubin ≤ 1.5×ULN, ALT and AST ≤ 1.5×ULN, Serum Creatinine ≤
             1×ULN, Endogenous Creatinine Clearance＞50ml/min

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Evidence of CNS metastasis

          -  Seriously uncontrolled infection

          -  History of another malignancies except cured basal cell carcinoma of skin and
             carcinoma in-situ of uterine cervix

          -  Pretreated with Fulvestrant

          -  Pretreated with two or more lines of endocrine therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xichun Hu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xichun Hu, MD, PhD</last_name>
    <phone>64175590</phone>
    <phone_ext>5006</phone_ext>
    <email>huxicun@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Biyun Wang, MD</last_name>
    <phone>64175590</phone>
    <phone_ext>5000</phone_ext>
    <email>wangbiyun@msn.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xichun Hu, MD,PhD</last_name>
      <phone>64175590</phone>
      <phone_ext>5006</phone_ext>
      <email>huxicun@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Biyun Wang, MD</last_name>
      <phone>64175590</phone>
      <phone_ext>5000</phone_ext>
      <email>wangbiyun@msn.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 9, 2014</lastchanged_date>
  <firstreceived_date>May 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xichun Hu</investigator_full_name>
    <investigator_title>Vice Director of department of medical oncology</investigator_title>
  </responsible_party>
  <keyword>Chemotherapy</keyword>
  <keyword>Endocrine therapy</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Fulvestrant</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
